CAS 2102933-95-7

GSK-LSD1 Dihydrochloride

CAS : 2102933-95-7

Formule : C₁₄H₂₂Cl₂N₂

Degré de pureté : 98%

Masse moléculaire : 289.2439

Ref: IN-DA01EO5W

GSK-LSD1 dihydrochloride

CAS : 2102933-95-7

GSK-LSD1 dihydrochloride

Degré de pureté : ≥98%

Masse moléculaire : 289.24g/mol

Ref: 54-BUP12461

GSK-LSD1 dihydrochloride

CAS : 2102933-95-7

GSK-LSD1 dihydrochloride: potent LSD1 inhibitor, >1000x selective over MAO-A/B, LSD2, IC50: 16 nM.

Formule : C₁₄H₂₂Cl₂N₂

Degré de pureté : 98.72% - >99.99%

Couleur et forme : Solid

Masse moléculaire : 289.24

Ref: TM-T2315

GSK LSD1 Dihydrochloride

Produit contrôlé

CAS : 2102933-95-7

Applications GSK LSD1 Dihydrochloride is an irreversible mechanism-based inhibitor of LSD1. Lysine-specific demthylase 1 (LSD1) belonges to the flavin adenine dinucleotide (FAD) family-dependant amine oxidases that include MAOs and PAOs. Inhibits cell proliferation in cancer cell lines.
References Shi, Y. et al.: Cell 119, 941 (2004); Forneris, F. J. Biol. Chem. 280, 41360 (2005);

Formule : C₁₄H₂₂Cl₂N₂

Couleur et forme : Neat

Masse moléculaire : 342.407

Ref: TR-G797570

GSK-LSD1 dihydrochloride

CAS : 2102933-95-7

GSK-LSD1 is a potential drug for the treatment of cervical cancer and myeloid leukemia. GSK-LSD1 has been shown to induce autophagy, which is a process by which cells break down and recycle their own cellular components. This process also plays a key role in the development of bowel disease, as well as inflammatory bowel disease and leukemias. GSK-LSD1 was shown to inhibit the growth of human myeloid leukemia cells (THP-1) in vitro and reduced the number of leukemic mice with leukemia. The mechanism by which GSK-LSD1 inhibits tumor cell proliferation is unclear, but may be related to its ability to inhibit cell factor or stem cell factor expression.

Formule : C₁₄H₂₂Cl₂N₂

Degré de pureté : Min. 95%

Masse moléculaire : 289.24 g/mol

Ref: 3D-CJD93395